TY - JOUR
T1 - Cognitive impairment occurs in children and adolescents with multiple sclerosis
T2 - Results from a United States network
AU - Julian, Laura
AU - Serafin, Dana
AU - Charvet, Leigh
AU - Ackerson, Joseph
AU - Benedict, Ralph
AU - Braaten, Ellen
AU - Brown, Tanya
AU - O'Donnell, Ellen
AU - Parrish, Joy
AU - Preston, Thomas
AU - Zaccariello, Michael
AU - Belman, Anita
AU - Chitnis, Tanuja
AU - Gorman, Mark
AU - Ness, Jayne
AU - Patterson, Marc
AU - Rodriguez, Moses
AU - Waubant, Emmanuelle
AU - Weinstock-Guttman, Bianca
AU - Yeh, Ann
AU - Krupp, Lauren B.
N1 - Funding Information:
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LJ is currently employed by Genentech. RHBB has served as a consultant for Actelion, Biogen Idec, Bayer, and Novartis; received grant/research support from Accorda, Biogen Idec, and Shire; and also receives royalties from Psychological Assessment Resources. TC has served as a consultant for Biogen-Idec, Sanofi Aventis, Novartis, EMD-Serono, and Teva Neurosciences, and has received grant support from Merck-Serono for unrelated activities. MG has research funding from NIH and Actelion. He has done consulting for Actelion, Shire HGT and Orphazyme and DMSB for Stem cells, Inc; Amicus and Shire HGT. EW has acted as an advisor/consultant/advisory board member or speaker for Actelion, Roche, Sanofi Aventis, and Teva, and has received research support from Biogen Idec, Roche, and Sanofi-Aventis. BWG has participated in speakers bureaus and served as a consultant for Biogen Idec, Teva Neurosciences, EMD Serono, Pfizer, Novartis, Genzyme, and Acorda; excluding Genzyme, she also has received grant/research support from the agencies listed above as well as ITN, Questcor, and Shire. LBK serves as a consultant and/or on the speakers’ bureau for Teva Neurosciences, Biogen Idec, EMD Serono, MEDA Corp, Acorda, Betaseron/Bayer Healthcare Pharmaceuticals, Gerson Lehrman Group, Guidepoint Global, Adler, Cohen, Harvey, Wakeman & Guekguezian, and Daniel J. Edelman; receives royalties from Genzyme, Zymogenetics, Ortho-McNeill Pharmaceutical, and ER Squibb & Sons; and receives research support from Genentech, BiogenIdec, Teva Neurosciences, Celgene Corporation, Garnett McKeen Laboratory Incorporated, NIH, Slomo and Cindy Silvian Foundation, MS Foundation, and the Lourie Foundation. Rest of the authors report no disclosures.
Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by the National Multiple Sclerosis Society.
PY - 2013/1
Y1 - 2013/1
N2 - In the largest sample studied to date, we measured cognitive functioning in children and adolescents with pediatric multiple sclerosis (n = 187) as well as those with clinically isolated syndrome (n = 44). Participants were consecutively enrolled from six United States Pediatric Multiple Sclerosis Centers of Excellence. Participants had a mean of 14.8 ± 2.6 years of age and an average disease duration of 1.9 ± 2.2 years. A total of 65 (35%) children with multiple sclerosis and 8 (18%) with clinically isolated syndrome met criteria for cognitive impairment. The most frequent areas involved were fine motor coordination (54%), visuomotor integration (50%), and speeded information processing (35%). A diagnosis of multiple sclerosis (odds ratio = 3.60, confidence interval = 1.07, 12.36, P =.04) and overall neurologic disability (odds ratio = 1.47, confidence interval = 1.10, 2.10, P =.03) were the only independent predictors of cognitive impairment. Cognitive impairment may occur early in these patients, and prompt recognition is critical for their care.
AB - In the largest sample studied to date, we measured cognitive functioning in children and adolescents with pediatric multiple sclerosis (n = 187) as well as those with clinically isolated syndrome (n = 44). Participants were consecutively enrolled from six United States Pediatric Multiple Sclerosis Centers of Excellence. Participants had a mean of 14.8 ± 2.6 years of age and an average disease duration of 1.9 ± 2.2 years. A total of 65 (35%) children with multiple sclerosis and 8 (18%) with clinically isolated syndrome met criteria for cognitive impairment. The most frequent areas involved were fine motor coordination (54%), visuomotor integration (50%), and speeded information processing (35%). A diagnosis of multiple sclerosis (odds ratio = 3.60, confidence interval = 1.07, 12.36, P =.04) and overall neurologic disability (odds ratio = 1.47, confidence interval = 1.10, 2.10, P =.03) were the only independent predictors of cognitive impairment. Cognitive impairment may occur early in these patients, and prompt recognition is critical for their care.
KW - clinically isolated syndrome
KW - cognition
KW - demyelination
KW - multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84871582482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871582482&partnerID=8YFLogxK
U2 - 10.1177/0883073812464816
DO - 10.1177/0883073812464816
M3 - Article
C2 - 23155206
AN - SCOPUS:84871582482
SN - 0883-0738
VL - 28
SP - 102
EP - 107
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 1
ER -